Solid Biosciences' (SLDB) DMD Drug Gets Fast Track Tag, Stock Up
Solid Biosciences Inc. received FDA Fast Track designation for SGT-003, a next-generation gene therapy for Duchenne muscular dystrophy (DMD), using AAV-SLB101 capsid. This designation aims to expedite development and review, following encouraging pre-clinical data. The company's stock surged 68.4% post-announcement. A phase I/II study will assess SGT-003's safety and efficacy in pediatric DMD patients.
Reference News
Solid Biosciences Inc. received FDA Fast Track designation for SGT-003, a next-generation gene therapy for Duchenne muscular dystrophy (DMD), using AAV-SLB101 capsid. This designation aims to expedite development and review, following encouraging pre-clinical data. The company's stock surged 68.4% post-announcement. A phase I/II study will assess SGT-003's safety and efficacy in pediatric DMD patients.